News

Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...
Regeneron's weight-loss drug helps patients on Wegovy preserve muscle
Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...
Regeneron: Negative Scenario Is Being Realized (Rating Downgrade)
Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.
STAT4d
Pharmalittle: We’re reading about FDA probing deaths after Sarepta treatment, a Regeneron plan for charities, and more
The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
BioPharma Dive12d
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...
GlobalData on MSN4d
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...
pharmaphorum9d
Dupixent is first FDA-approved drug for rare skin disease
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...
Stocktwits on MSN9d
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease Affecting Elderly, But Retail Stays Dull
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
Forbes27d
Is Regeneron Stock Undervalued At $500? - Forbes
To add to Regeneron’s challenges, the U.S. Food and Drug Administration (FDA) recently rejected a pre-filled syringe variant of Eylea HD, citing problems with a third-party supplier.